Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard


Aurora Cannabis
TSX: ACB
NYSE: ACB
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: >2000 as of 12/2018
Established: 2013
CEO: Terry Booth

Summary

Fiscal Year-End: June 30
Licensed Facilities: 14
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: 73,579 at 12/31/18
Headquarters: Vancouver, BC

Financials (12/31/18)

Cash on hand: $48.0mm
Fixed Investment: $534.2mm
Shareholders’ Equity: $4.29 billion
Net Revenue – Last Quarter: $54.2mm
Adj. Gross Margin: 52.4%
EPS : -$0.25

Capital Structure (02/08/18)

Last Equity Fin: $345mm Convertible Notes at US$7.23
Basic Shares: 1.017 billion
Warrants: 23.9 million
Options: 70.1 million
Diluted Shares: 1.176 billion

Company Brief

Aurora is one of the world’s largest and fastest growing cannabis companies. Following the acquisition of MedReleaf, the company has more than 1,500 employees, 14 facilities ( three EU GMP certified), and a funded annual production capacity of more than 625,000 kilograms per year. The Company is vertically integrated and horizontally diversified across every key segment of the cannabis value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company’s purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. Aurora’s growing constellation of subsidiaries and strategic partnerships provide differentiation in terms of geographic reach, production, technology, product offering, and execution.

With a growing number of countries adopting medical cannabis legislation, the Company has embarked on an aggressive international expansion strategy that currently sees Aurora with operations and/or sales in 24 countries across five continents.

Featured Video

James West interviews CCO Cam Battley about the company’s Q1 2019 financial results, which saw Aurora’s pro-forma revenue increase 333 percent to $35.8 million. Battley says that Aurora’s earnings are “by the far the most powerful revenue quarter that any cannabis company has delivered.”


Differentiators

Canadian Operations

  • 14 global production facilities in operation or under construction with 3 EU GMP certified
  • Acquisition of CanniMed and MedReleaf leave the company with nine facilities in Canada
  • Ownership of CanvasRx, the largest operator of cannabis clinics in Canada with over 35 clinics open
  • Strong product portfolio brands including Aurora, CanniMed, MedReleaf San Rafael ’71, Woodstock, AltaVie, Evio, Bidol, and Plant Hemp
  • Same-day delivery in Alberta and innovative mobile ordering app
  • Supply agreements across 12 provinces and territories
  • Agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart to distribute and sell medical cannabis
  • 40 clinical studies completed or ongoing and over 73,000 medical patients served
  • Large investment portfolio including TGOD, Radient Technologies, Hempco, Alcanna (formerly Liquor Stores N.A.), and more

Global Operations

  • Active in five continents and 24 countries
  • 22.9% ownership of Australia’s Cann Group (ASX: CAN)and 51% ownership of Aurora Nordic in Denmark
  • Leading market share in the German medical market and ownership of German distribution company Pedanios
  • Wholly owned subsidiary ICC Labs gives the company a platform in Latin America
  • Acquired European hemp company Agropro and sister company Borela
  •  Supply agreements in the Czech Republic, Italy, South Africa, Luxembourg, and Mexico
  • Recently announced 51% ownership interest in Gaia Pharma Lda. To establish a local facility to produce medical cannabis and derivative product
  • HealthUK granted Aurora approval for its first shipment of medical cannabis into the UK from Canada under its new legal framework effective as of November 1, 2018
  • Approved for the first cannabis cultivation facility in Malta
  • First LP to receive a cannabis import permit from the Polish Ministry of Health
  • Structured investment in spin-off Australis Capital, which positions the company to benefit from eventual U.S. legalization

Institutional Analyst Coverage

MATT BOTTOMLEY
Canaccord Genuity

BRETT HUNDLEY
Seaport

MARTIN LANDRY
GMP Securities

GRAEME KREINDLER
Eight Capital

VIVIEN AZER
Cowen and Company

DOUGLAS MIEHM
RBC Capital Markets

JASON ZANDBERG
PI FINANCIAL

TAMY CHEN
BMO Nesbitt Burns

GREG MCLEISH, CFA
Mackie Research

NIKOLAAS FAES
Bryan Garnier & Co

ROB WERTHEIMER
Melius Research


Curated Stories & News


Visit Aurora Cannabis
at www.auroramj.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.